| Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, ... PloS one 4 (10), e7287, 2009 | 320 | 2009 |
| Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial MG Ghi, A Paccagnella, D Ferrari, P Foa, D Alterio, C Codecà, F Nolè, ... Annals of Oncology 28 (9), 2206-2212, 2017 | 175 | 2017 |
| A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. RJ Sullivan, JS Weber, SP Patel, R Dummer, WH Miller, D Cosgrove, ... Journal of Clinical Oncology 33 (15_suppl), 9007-9007, 2015 | 72 | 2015 |
| The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer G Mauri, E Bonazzina, A Amatu, F Tosi, K Bencardino, V Gori, ... Cancers 13 (1), 137, 2021 | 65 | 2021 |
| Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer A Sartore-Bianchi, K Bencardino, A Cassingena, F Venturini, C Funaioli, ... Cancer treatment reviews 36, S1-S5, 2010 | 46 | 2010 |
| Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer A Amatu, L Barault, C Moutinho, A Cassingena, K Bencardino, S Ghezzi, ... Annals of Oncology 27 (6), 1062-1067, 2016 | 39 | 2016 |
| A phase II-III study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally … MG Ghi, A Paccagnella, D Ferrari, P Foa, M Cossu Rocca, E Verri, ... Journal of Clinical Oncology 31 (15_suppl), 6003-6003, 2013 | 27 | 2013 |
| Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of … A Sartore-Bianchi, A Amatu, E Bonazzina, S Stabile, L Giannetta, G Cerea, ... Targeted Oncology 12, 525-533, 2017 | 16 | 2017 |
| Linitis plastica of the rectum as a clinical presentation of metastatic lobular carcinoma of the breast F Venturini, V Gambi, S Di Lernia, A Vanzulli, M Bramerio, K Bencardino, ... Journal of clinical oncology: official journal of the American Society of …, 2016 | 11 | 2016 |
| GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally … MG Ghi, A Paccagnella, D Ferrari, P Foa, D Alterio, C Codecà, F Nolè, ... Ann Oncol 28 (9), 2206-2212, 2017 | 9 | 2017 |
| The evolutionary landscape of treatment for BRAF (V600E) mutant metastatic colorectal cancer. Cancers. 2021; 13: 137 G Mauri, E Bonazzina, A Amatu, F Tosi, K Bencardino, V Gori, ... s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in …, 2021 | 3 | 2021 |
| Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report G Mauri, V Gori, G Patelli, L Roazzi, F Rizzetto, L De Carlis, A Mariani, ... World Journal of Surgical Oncology 21 (1), 118, 2023 | 1 | 2023 |
| 72P Molecular characterization of advanced primary cardiac sarcomas AG Agostara, G Patelli, K Bencardino, C Lauricella, S Pierri, G Ciarlo, ... ESMO Open 8 (1), 2023 | | 2023 |
| Angelo Vanzulli T Cipani, E Forti, E Tarenzi, A Sartore-Bianchi, R Pugliese, S Siena Oncol, 2014 | | 2014 |
| Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, P Saletti, ... | | 2009 |
| Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab A Sartore-Bianchi, A Sporchia, G Cerea, MR Maugeri, T Cipani, I Andreotti, ... Current Cancer Therapy Reviews 3 (4), 249-254, 2007 | | 2007 |
